Regional Agency for Health and Social Care of Emilia-Romagna, Bologna, Italy.
European Centre for Disease Prevention and Control, Solna, Sweden.
Euro Surveill. 2021 Nov;26(46). doi: 10.2807/1560-7917.ES.2021.26.46.2002094.
BackgroundInvasive infections caused by have high clinical and epidemiological relevance. It is therefore important to monitor the trends using suitable methods.AimThe study aimed to describe the trends of bloodstream infections (BSI) caused by meticillin-resistant (MRSA) and meticillin-susceptible (MSSA) in the European Union (EU) and the European Economic Area (EEA).MethodsAnnual data on BSI from 2005 to 2018 were obtained from the European Antimicrobial Resistance Surveillance Network (EARS-Net). Trends of BSI were assessed at the EU/EEA level by adjusting for blood culture set rate (number of blood culture sets per 1,000 days of hospitalisation) and stratification by patient characteristics.ResultsConsidering a fixed cohort of laboratories consistently reporting data over the entire study period, MRSA percentages among BSI decreased from 30.2% in 2005 to 16.3% in 2018. Concurrently, the total number of BSI caused by increased by 57%, MSSA BSI increased by 84% and MRSA BSI decreased by 31%. All these trends were statistically significant (p < 0.001).ConclusionsThe results indicate an increasing health burden of MSSA BSI in the EU/EEA despite a significant decrease in the MRSA percentage. These findings highlight the importance of monitoring antimicrobial resistance trends by assessing not only resistance percentages but also the incidence of infections. Further research is needed on the factors associated with the observed trends and on their attributable risk.
凝固酶阴性葡萄球菌( )引起的侵袭性感染具有重要的临床和流行病学意义。因此,使用合适的方法监测 趋势非常重要。
本研究旨在描述耐甲氧西林凝固酶阴性葡萄球菌(MRSA)和甲氧西林敏感凝固酶阴性葡萄球菌(MSSA)引起的血流感染(BSI)在欧盟(EU)和欧洲经济区(EEA)的趋势。
从欧洲抗菌药物耐药性监测网络(EARS-Net)获得 2005 年至 2018 年每年的 BSI 数据。通过调整血培养套率(每 1000 天住院的血培养套数)和按患者特征分层,在欧盟/EEA 水平评估 BSI 趋势。
考虑到在整个研究期间始终有固定数量的实验室报告数据,MRSA 在 BSI 中的百分比从 2005 年的 30.2%下降到 2018 年的 16.3%。与此同时, 引起的 BSI 总数增加了 57%,MSSA BSI 增加了 84%,MRSA BSI 减少了 31%。所有这些趋势均具有统计学意义(p<0.001)。
尽管 MRSA 百分比显著下降,但 EU/EEA 中 MSSA BSI 的健康负担仍在增加。这些发现强调了通过评估不仅包括耐药百分比,还包括感染发生率来监测抗菌药物耐药趋势的重要性。需要进一步研究与观察到的趋势相关的因素及其归因风险。